More recently, a short-acting IL-22-bispecific fusion protein that selectively targets the liver and pancreas alleviated hepatic steatosis and prevented the development of hepatic fibrosis in a 10-fold lower dose than the long-acting form of IL-22 administered in previous pre-clinical studies [83]. The gene discussed is IL22; the disease is fatty liver disease.